Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603941 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
A Phase 1 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00603941 is a Phase 1 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 19 participants.
The verdict
NCT00603941, a Phase 1 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The Phase I/II study will be conducted as an open label, multiple center study of CS-7017, an experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid cancer. Biopsies will be obtained from patients with accessible tumor at baseline, two-weeks after the first CS-7017 dosage (prior to the start of combination therapy) and at the end of the first study cycle (week 3 of combination therapy), in order to evaluate the effects of the study drug alone and in combination with the chemotherapy agent on the tumor. Treatment will continue until disease progression or the development of intolerable toxicities.
Interventions
- DRUG Paclitaxel
- DRUG CS-7017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603941
The ClinicalTrials.gov registry entry for NCT00603941 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00603941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00603941 about?
NCT00603941 is a clinical study titled "A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel". The Phase I/II study will be conducted as an open label, multiple center study of CS-7017, an experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid cancer. Biopsies will be obtained from patients with accessible tumor at baseline, two-weeks after the first CS-701...
What is the current status of trial NCT00603941?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2008-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00603941?
The interventions under investigation include: Paclitaxel (DRUG), CS-7017 (DRUG).
Who is sponsoring clinical trial NCT00603941?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.